DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in a new awareness campaign. The project kicked off Friday, World Diabetes Day ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings. The company's revenue grew over 21% year-on-year to $1.21 ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...